XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Clinical Trials
1
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
Active, not recruiting
1
100.0%
No approval data available
- AbbVie's Rinvoq (upadacitinib) received FDA approval in April 2025 as the first oral JAK inhibitor for adult giant cell arteritis patients, based on Phase III SELECT-GCA trial results showing 46.4% sustained remission versus 29% placebo. - Novartis' Cosentyx (secukinumab) failed to meet its primary endpoint in the Phase III GCAptAIN trial in July 2025, showing no significant improvement in sustained remission at 52 weeks compared to placebo. - Over six pharmaceutical companies are actively developing more than six therapeutic candidates for giant cell arteritis, the most common vasculitis in individuals over 50 that can cause permanent vision loss without treatment. - The expanding pipeline includes monoclonal antibodies and small molecule inhibitors targeting various inflammatory pathways, reflecting growing innovation in addressing this critical autoimmune condition.
- DelveInsight's 2025 report reveals over 80 companies are actively developing more than 80 pipeline therapies for pancreatic ductal adenocarcinoma treatment. - Key pharmaceutical companies including Genentech, Revolution Medicines, and Merck Sharp & Dohme are conducting Phase 3 trials with promising novel therapeutic approaches. - Emerging therapies such as Onvansertib, Nadunolimab, and Zimberelimab represent diverse mechanisms of action targeting treatment resistance and immune suppression in pancreatic cancer. - Recent regulatory approvals include Anocca's VIDAR-1 Phase I/II trial targeting KRAS-positive advanced pancreatic cancer, demonstrating growing focus on precision medicine approaches.
